Halozyme Therapeutics, Inc. (HALO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

Halozyme Therapeutics, Inc. ( HALO ) H.C. Wainwright 28th Annual Global Investment Conference September 16, 2026 10:00 AM EDT Company Participants Helen Torley - President, CEO & Director Darren Snellgrove - Senior VP & CFO Conference Call Participants Mitchell Kapoor - H.C. Wainwright & Co, LLC, Research Division Presentation Mitchell Kapoor H.C. Wainwright & Co, LLC, Research Division Hello, everyone. My name is Mitchell Kapoor. I'm a senior biotech analyst at H.C. Wainwright. Thank you for joining us for our third day of the H.C. Wainwright Conference here in New York. Today, I have the pleasure of welcoming the Halozyme team, and I have the Chief Executive Officer and President, Helen Torley; and Chief Financial Officer, Darren Snellgrove. Nice to have you both here. Helen Torley President, CEO & Director I appreciate the invite to be here. Thanks. Darren Snellgrove Senior VP & CFO Thanks for joining us. Question-and-Answer Session Mitchell Kapoor H.C. Wainwright & Co, LLC, Research Division So maybe I'd like to start off every fireside chat by just level setting for those who either may not be familiar with the story or not up to speed with the latest progress. Maybe you could just give an overview of Halozyme. Helen Torley President, CEO & Director Yes. Halozyme is transforming how biologics are delivered subcutaneously, and we're entering just a terrific period of value creation as a result of that. How do we do this? We today have 4 technologies that enable subcutaneous delivery. ENHANZE, which is our flagship product, but we acquired recently 2 hyperconcentration technologies that will be entering the clinic and will offer a brand-new value proposition for patients to be able to deliver biologics in volumes as low as 2 mls via small volume auto-injectors, and we also have our own auto-injector line. ENHANZE has really been a terrific. We describe it as